1 day+20.80%
1 week+38.89%
Current month+40.93%
1 month+35.61%
3 months+66.43%
6 months+82.25%
1 week 81.9
Extreme 81.9
122
1 month 76
Extreme 76
122
Current year 37.55
Extreme 37.55
122
1 year 37.55
Extreme 37.55
122
3 years 37.55
Extreme 37.55
122
5 years 37.55
Extreme 37.55
122
10 years 37.55
Extreme 37.55
122
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2017-01-12
Chief Executive Officer - 2017-01-12
Director of Finance/CFO - 2019-09-22
Director TitleAgeSince
Director/Board Member 52 2019-07-24
Chairman - 2017-01-12
Director/Board Member - 2025-10-22
Change 5-day change 1-year change 3-year change Capi.($)
+20.80%+38.89% - - 483M
-1.78%-1.68%+1.48%+15.31% 48.42B
+0.85%-0.70%+460.88%+563.55% 43.66B
-2.40%-0.23%+8.13%+71.41% 39.51B
-2.01%-0.85%+23.85%+8.73% 38.95B
-0.50%+0.85%+20.60%+49.65% 32.61B
+0.38%-3.23% - - 16.32B
-0.59%-2.06%+26.35%+118.09% 16.15B
+0.49%+0.92%+4.11%+23.67% 14.16B
-0.43%+4.70%+78.74%+33.31% 13.37B
Average +1.48%+4.16%+78.02%+110.46% 26.36B
Weighted average by Cap. -0.87%+0.66%+95.83%+132.95%

Financials

2024 2025
Net sales 803K 25.09K 21.66K 20.38K 18.51K 34.77K 2.39M 35.44K 239K 93.26K 1.2M 94.17K 92.15K 3.99M 50.29M 1.57M 1.36M 1.28M 1.16M 2.18M 150M 2.22M 14.94M 5.84M 75.18M 5.9M 5.77M 250M
Net income -440M -13.76M -11.88M -11.17M -10.15M -19.06M -1.31B -19.43M -131M -51.14M -658M -51.63M -50.53M -2.19B -1.11B -34.57M -29.85M -28.08M -25.51M -47.91M -3.3B -48.84M -329M -129M -1.65B -130M -127M -5.5B
Net Debt - -
Logo Elixiron Immunotherapeutics (Cayman) Limited
Elixiron Immunotherapeutics Cayman Ltd is an investment holding company located in Taiwan, focusing on developing innovative precision immunotherapy drugs for multiple diseases. The Company operates as a new drug research and development enterprise, with products currently in clinical development. Its pipeline is centered on innovative drug development, covering neurodegenerative disorders, immune-related diseases, and oncology. The main clinical-stage candidates are EI-1071 (Enrupatinib) and EI-001 (Indemakitug). EI-1071 (Enrupatinib) is a proprietary small-molecule drug targeting neurodegenerative diseases, with Alzheimer’s disease as its primary indication, currently in Phase II clinical trials. EI-001 (Indemakitug) is an anti-IFNy monoclonal antibody designed for precise immunomodulation in autoimmune diseases.
Employees
-
Date Price Change Volume
26-08-14 NT$115.00 +20.80% 6,061,484
26-08-13 NT$95.20 +1.38% 1,739,987
26-08-12 NT$93.90 +1.84% 2,841,765
26-08-11 NT$92.20 +10.02% 2,818,076
26-08-10 NT$83.80 +1.21% 831,423
  1. Stock Market
  2. Stocks
  3. 7871 Stock